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Modeling perfusion at small scale using ambr15TM
Delia Lyons, Dustin Davis, Irfan Hodzic and Scott Ross
Cell Sciences and Development, SAFC Sigma-Aldrich
2909 Laclede Avenue, Saint Louis, MO 63103, USA

Abstract

•

Small scale models

Reaching cell densities higher than 80 million with the minimum possible
perfusion rates is a goal for an increasing proportion of processes developed by
biopharmaceutical companies. With the goal of fulfilling the industry needs for
better commercial and customized perfusion media, SAFC evaluated different
small-scale perfusion models to achieve an efficient work flow that can
accommodate perfusion systems. SAFC successfully uses an optimized work
flow for the development of media and feeds for fed-batch cell culture that
integrates high-throughput screening, statistical tools and bench-top bioreactor
scale studies. In this model, 96-deep well plates are used for the initial high
throughput screening, followed by further development in spin tubes or shake
flasks. At this time, there is no commercially available cell separation device that
can be used for scales of 30mL or lower. The application of the 96-deep well
plate or spin tubes model for perfusion showed to have severe limitations,
specifically when trying to optimize processes to extremely low cell specific
perfusion rates (CSPR). In order to develop media that can sustain the desired
high densities and productivity at the desired low CSPRs, we needed a
representative model that provided enough throughput to apply our statistical
analysis. With this goal, we evaluated an alternative small scale model using the
automation and process control offered by the ambr15TM. In this work, we show
how ambr15TM fits in the work flow for perfusion media development and its
comparability to a chemostat bioreactor.

Figure 1. High seed density batch culture
•
•
•
•

Table 1. Bioreactor chemostat
Cell growth (1A), protein production (1B) and specific productivity (1C)

Figure 2. Bolus-chemostat using ambr15TM

Material and Methods
•
•

•

Peak cell densities between 8-14x106vc/mL were observed (Fig. 2A). Comparable peak cell
density was observed for a given medium in all dilution rates. However, the peak was slightly
higher and it was reached one day sooner at lower dilution rates (data not shown). The steady
state cell density was comparable for a given medium at the three different dilutions performed
(data not shown).
Peak cell density ranked as M1 ≥ M3 > M4 > M2 (Fig. 2C)
At steady state growth rates were balanced with the dilution rates, however differences in
CSPR were observed. At comparable CSPRs specific growth rate ranked as M1> M4> M3 ≥
M2 (Fig. 2D)
Specific productivity decreased after the initial growth phase in all media but M2 (Fig. 2B).
Once steady state was reached, specific productivity was constant for media M2 and M4,
increased for media M1 and decreased for medium M3. Specific productivity at steady state
and comparable CSPRs ranked as M1 > M4 ≥ M2 > M3 (Fig. 2E)

An in-house generated CHOZN® GS cell line producing IgG1 was used in this
study. Cells were scaled up in EXCELL® CD Fusion. The carry over in all
experiments was between 5-10%. Four different chemically defined SAFC’s
media known to have different growth and production profiles were used during
the course of this study.
Cell viability and density were measured using Vi-cell XR (Beckman Coulter,
California), and titers were measured using ForteBio Octet (Pall Co., California).
Equations used for this study were as follow:

•

•

•

In this study, batch model and chemostat at small scale were performed and
compared to a chemostat bioreactor. Batch mode was performed in spin tubes
(TPP, Switzerland) and small scale chemostat was performed in ambr15TM
(Sartorius, Germany). The working volumes were 30 and 14mL, respectively. The
small scale cultures were compared to a 5L bioreactor scale chemostat (BioStat
B, Sartorius, Germany). Dilution rates of 0.22, 0.26, 0.3 were evaluated in small
scale, while 0.28 followed by 0.2 were evaluated at the bioreactor scale. Media
exchanges were started on day 1 for small scale models and on day 5 for
bioreactor scale.

•

Peak cell densities between 10-15x106vc/mL were observed. Culture longevity was inversely
correlated to the peak cell density (Fig. 1A)
Cells stopped producing at the peak density with the exception of M4 (Fig. 1B).
Specific growth rates ranked as M3 > M4> M1 > M2 (data not shown)
Specific productivity ranked as M4 > M2 ≥ M1 > M3 (Fig. 1C)

Specific growth (3A) productivity (3B)

Conclusions and future work
•

The use of batch TPPs or well plates allows for high throughput screening that can be used for
the selection of media to be used for perfusion. However, this work shows that observations
made on TPPs do not always transfer to a chemostat system. It is not known at this time if this
observation is due to differences between a dynamic and a continuous process or due to process
parameters such as pH and DO and this is currently being investigated.

•

Differences when ranking different media based on their specific growth and productivity between
TPPs and ambr15TM were found. The ranking in specific productivity was more similar between
TPPs and ambr15TM if the comparison is made on the growth phase of the chemostat. While the
absolute values are not comparable (Fig. 3B) the ranking and behavior on the stability of
productivity was comparable (Fig. 1C and 2B). This fact underlines the need for a model that can
represent a steady state as opposed to a dynamic model.

•

The chemostat run in ambr15TM is a semi-chemostat. Because of the discontinuity of the model
when compared to a fully continuous process, limitations on growth and potentially productivity
can become visible at higher dilution rates than in bioreactors (Figure 3A and B).

•

Work published by Heltmann (2015) and Henry et. al (2008) showed comparability in specific
rates between chemostat and perfusion at similar CSPR. In this work we showed that ambr15TM
can be used as a tool to model a chemostat and evaluate different media that ultimately is going
to be used in perfusion mode. We expect that this model is going to allow us to evaluate media
with very different characteristics in order to perform media component optimization at a relatively
high throughput.

Cell growth (2A) and specific productivity (2B) at D 0.22vvd

where

for continuous processes or,

for batch processes.

VCD at steady state (2C), specific growth rate (2D) and specific productivity (2E) at D 0.22, 0.26 and 0.3vvd
CSPR: cell specific perfusion rate (nL/cell*d)
D: dilution rate (vvd)
F: volume of medium exchanged (mL)
IVCD: integral viable cell density (cell*d/mL)
µ: growth rate (d-1)
N: number of media exchanges per day
P: IgG concentration (mg/L)
qp: specific productivity (pcd)
X: cell density (vc/mL)
V: working volume (mL)
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The steady state cell density was comparable between the bioreactor (6.7x106vc/mL) and the
ambr15TM (7.0x106vc/mL) at a dilution rate of 0.28 or 0.30vvd, respectively . However, the cell
density was higher in the bioreactors (8.1x106vc/mL) when compared to ambr15TM
(6.5x106vc/mL) at a dilution rate of 0.2 or 0.22vvd, respectively.
At the higher dilution rates of 0.28 or 0.3vvd, specific growth rates and CSPRs were
comparable between the bioreactor and the ambr15TM. However, at the lower dilution rates of
0.2 or 0.22vvd while growth rate were comparable, significant differences in CSPRs were
observed (Fig. 3A).
When comparing chemostats with batch TPPs at equivalent CSPR (Konstantinov et al., 2006),
significant differences in growth rates were observed (Fig. 3A). However, in the chemostat
growth rate is initially higher (0.7d-1) and as CSPR decreases, growth rate gradually decreases
until it stabilizes to the dilution rate. During the growth phase of the chemostat, specific growth
rates were comparable between ambr15TM and TPPs at equivalent CSPR (Fig. 3A).
Specific productivity was comparable between ambr15TM at steady state and TPPs at peak cell
density, but not during ambr15TM growth phase (Fig. 3B). Specific productivity was significantly
lower in the bioreactor than in ambr15TM.

3. Comparison of TPPs batch, ambr and bioreactor chemostat
• The growth profile in the bioreactor chemostat was comparable to ambr15TM chemostat (Fig.
2A). Initially cells grew to a higher peak cell density (9x106vc/mL) and as growth rate decreased it
reached a steady state of 6.7x106vc/mL at 0.3vvd (Table 1).
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